Bio-Techne Corporation (TECH) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $264.0M (period ending 2009-06-30) to $1.22B (period ending 2025-06-30) — a 10.0% annual pace across 16 year(s) of filed history.
- Net margin compressed from 39.9% to 6.0% over that same span.
- Across 51 tracked quarters, the strongest was $316.2M (quarter ending 2025-03-31) and the weakest was $65.5M (quarter ending 2009-12-31).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $1.22B | 2025-06-30 | 10-K | 0001558370-25-011716 |
| Gross profit | $790.3M | 2025-06-30 | 10-K | 0001558370-25-011716 |
| Operating income | $102.3M | 2025-06-30 | 10-K | 0001558370-25-011716 |
| Net income | $73.4M | 2025-06-30 | 10-K | 0001558370-25-011716 |
| Diluted EPS | $0.46 | 2025-06-30 | 10-K | 0001558370-25-011716 |
| Total assets | $2.56B | 2025-06-30 | 10-K | 0001558370-25-011716 |
| Cash & equivalents | $162.2M | 2025-06-30 | 10-K | 0001558370-25-011716 |
| Operating cash flow | $287.6M | 2025-06-30 | 10-K | 0001558370-25-011716 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $311.4M | 2026-03-31 | 10-Q | 0001104659-26-056302 |
| Gross profit | $208.3M | 2026-03-31 | 10-Q | 0001104659-26-056302 |
| Operating income | $75.5M | 2026-03-31 | 10-Q | 0001104659-26-056302 |
| Net income | $51.0M | 2026-03-31 | 10-Q | 0001104659-26-056302 |
| Diluted EPS | $0.32 | 2026-03-31 | 10-Q | 0001104659-26-056302 |
| Total assets | $2.55B | 2026-03-31 | 10-Q | 0001104659-26-056302 |
| Cash & equivalents | $209.8M | 2026-03-31 | 10-Q | 0001104659-26-056302 |
| Operating cash flow | $27.6M | 2025-09-30 | 10-Q | 0001104659-25-107053 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Bio-Techne Corporation’s revenue scale is substantial, having grown from $264.0 million in 2009 to $1.22 billion in the most recent annual period, reflecting a steady 10.0% annual growth rate over 16 years. This trajectory underscores the company’s expansion and market penetration. However, net income margins have compressed from 39.9% to 6.0% during this period, indicating increasing pressure on profitability despite revenue growth.
The multi-year trend reveals a business model that has scaled significantly but faces challenges in maintaining high profit margins. The company’s operating cash flow, while robust at $287.6 million annually, dipped to $27.6 million in the most recent quarter, hinting at potential seasonality or operational efficiencies needing attention.
In upcoming filings, investors should monitor whether Bio-Techne can stabilize its margins amidst continued revenue expansion. The company’s ability to manage costs and improve profitability will be crucial in assessing its long-term sustainability and growth prospects. Additionally, the variability in quarterly performance, with a high of $316.2 million and a low of $65.5 million, suggests vigilance is needed regarding operational consistency across different quarters.
Source: SEC EDGAR company facts for CIK 0000842023 · filings index